NVIDIA's BioNeMo platform has been adopted by life sciences leaders including Eli Lilly and Thermo Fisher Scientific to accelerate AI-driven drug discovery.1
The platform is enabling pharmaceutical companies and lab equipment manufacturers to deploy AI foundation models for biological research and drug development.1 Eli Lilly's adoption signals strategic capital allocation by major pharma toward AI-powered development infrastructure.
Thermo Fisher Scientific, a global leader in laboratory equipment and services, is implementing BioNeMo to enhance its research capabilities.1 The company's involvement extends NVIDIA's reach beyond software into the physical lab equipment ecosystem.
Multiple AI-native biotech companies are launching foundation model platforms using BioNeMo.1 Natera, Basecamp Research, Owkin, Edison Scientific, and Boltz Lab are building specialized AI systems on the platform.
The BioNeMo framework provides pre-trained models and computational infrastructure for biological data analysis. Companies use the platform to process genomic sequences, protein structures, and molecular interactions at scale.
NVIDIA is positioning BioNeMo as industry-standard infrastructure for computational biology. The platform handles the training and deployment of large language models adapted for biological sequences rather than human language.
Pharmaceutical companies face development timelines exceeding 10 years and failure rates above 90% for drug candidates. AI platforms promise to compress discovery phases by identifying promising molecular targets faster than traditional laboratory screening.
The corporate capital flowing into AI drug discovery infrastructure reflects a broader shift in pharmaceutical R&D budgets. Companies are allocating resources to computational platforms that can process millions of molecular combinations in silico before physical synthesis.
BioNeMo's adoption across both established pharmaceutical manufacturers and venture-backed biotech startups indicates standardization around NVIDIA's AI infrastructure. This creates network effects as models trained by different organizations can potentially share architectural improvements.
The platform competes with proprietary internal AI systems at companies like Recursion Pharmaceuticals and Insitro, which have built custom infrastructure. BioNeMo offers a commercial alternative to in-house development.
